ERBB2 and breast cancer: This study aims to investigate the clinicopathological parameters that can predict the response to neoadjuvant treatment in HER2 + breast cancers and to examine the role of the immune system by exploring the role of TILs, CD8 + T lymphocytes and PD-L1 expression in order to gain a better understanding of it.